WCN24-101 KLF2 AGONISTS AS A NOVEL THERAPY FOR DIABETIC DISEASE

WCN24-101 KLF2 AGONISTS AS A NOVEL THERAPY FOR DIABETIC DISEASE

Saved in:

Bibliographic Details
Main Authors:	fang zhong, John He
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924005369
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Partial Role of KLF4 and KLF5 in Gastrointestinal Tumors
by: Jun-Chen Li, et al.
Published: (2021-01-01)

WCN24-1295 Prevalence and factors predicting non diabetic kidney disease in type 2 diabetic patients
by: Jasmine Sethi, et al.
Published: (2024-04-01)

WCN24-385 PREDICTING PATIENT RESPONSE TO STANDARD-OF-CARE THERAPIES IN GLOMERULAR DISEASES
by: Sean Eddy, et al.
Published: (2024-04-01)

Correlation of A2bAR and KLF4/KLF15 with Obesity-Dyslipidemia Induced Inflammation in Uygur Population
by: Cuizhe Wang, et al.
Published: (2016-01-01)

WCN24-432 FINERENONE IN CHINESE PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: A FIDELITY ANALYSIS
by: Ping Li, et al.
Published: (2024-04-01)

WCN24-1330 EFFECTS OF SGLT2 INHIBITORS AND GLP-1 RECEPTOR AGONISTS ON TOP OF RAS BLOCKADE IN UNINEFRECTOMIZED DB/DB MICE
by: María José Soler, et al.
Published: (2024-04-01)

A Multifunctional MIL-101-NH2(Fe) Nanoplatform for Synergistic Melanoma Therapy
by: Shang J, et al.
Published: (2025-01-01)

WCN24-1402 ANCA-ASSOCIATED GLOMERULONEPHRITIS IN DIABETIC KIDNEY DISEASE: CASE REPORT
by: Germán Landeros, et al.
Published: (2024-04-01)

WCN24-1327 EFFECTS OF PHOTOBIOMODULATION ON RENAL FUNCTION IN RATS WITH DIABETIC KIDNEY DISEASE
by: Garcia Villalba, et al.
Published: (2024-04-01)

KLF2 controls the apoptosis of neutrophils and is associated with disease activity of systemic lupus erythematosus
by: Hongshuai Zhao, et al.
Published: (2024-12-01)

WCN24-210 EVIDENCE OF MICROALBUMINURIA INCHILDREN DIAGNOSED WITH TYPE 2 DIABETES MELLITUS
by: Michael Yafi
Published: (2024-04-01)

Biological mechanisms of dopamine D2-like receptor agonist therapy in diabetes
by: Zachary Freyberg, et al.
Published: (2025-01-01)

The role of KLF4 in phagocyte activation during infectious diseases
by: Toni Herta, et al.
Published: (2025-04-01)

WCN24-905 The carbon footprint of dialysis therapies in Victoria, Australia
by: Stephen McDonald, et al.
Published: (2024-04-01)

WCN24-1422 MALNUTRITION IN HEMODIALYSIS PATIENTS WITH OR WITHOUT DIABETES
by: Valeria Aicardi, et al.
Published: (2024-04-01)

WCN24-1063 The role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in Diabetic Nephropathy and Non Diabetic Renal Disease in Diabetes Mellitus type2 Patients
by: Maru Navarro, et al.
Published: (2024-04-01)

New insight into the significance of KLF4 PARylation in genome stability, carcinogenesis, and therapy
by: Zhuan Zhou, et al.
Published: (2020-11-01)

WCN24-1272 Far-reaching health benefits of the physical exercise on diabetic kidney disease
by: Carla Victoria Carla Victoria, et al.
Published: (2024-04-01)

KLF feedback loops in innate immunity
by: Jessica M. Salmon, et al.
Published: (2025-06-01)

WCN24-2292 RENOPROTECTIVE EFFECTS OF THE ANGIOTENSIN II TYPE 2 RECEPTOR (AT2R) AGONIST, C21, AGAINST ACUTE ISCHEMIC KIDNEY INJURY IN FEMALE RATS
by: MARIA FERNANDA FUSSI, et al.
Published: (2024-04-01)

Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies
by: Syed Kazmi, et al.
Published: (2025-06-01)

TIEG1/KLF10 modulates Runx2 expression and activity in osteoblasts.
by: John R Hawse, et al.
Published: (2011-04-01)

WCN24-1657 NOVEL VARIANTS IN THE GATM GENE CAUSE FANCONI SYNDROME IN 2 CHILDREN
by: Larisa Prikhodina, et al.
Published: (2024-04-01)

WCN24-1077 NOVEL BIOMARKERS AND PREDICTION OF KIDNEY DISEASE PROGRESSION IN AUSTRALIAN FIRST NATION PEOPLE WITH AND WITHOUT DIABETES: THE eGFR STUDY
by: Richard MacIsaac, et al.
Published: (2024-04-01)

WCN24-714 AMBULATE DURING HEMODIALYSIS THERAPY – SHARING EXPERIENCE
by: Cinthia Vieira, et al.
Published: (2024-04-01)

WCN24-2325 EXECUTIVE IMPAIRMENT IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON REPLACEMENT THERAPY: PRELIMINARY DATA
by: gaston alvarez, et al.
Published: (2024-04-01)

WCN24-1734 QUALITY OF LIFE IN PATIENTS WITH CHRONIC KIDNEY DISEASE UNDERGOING RENAL REPLACEMENT THERAPY
by: I.V.A.N. ROSERO, et al.
Published: (2024-04-01)

Aberrant expression of TRIM44, transcriptionally regulated by KLF9, contributes to the process of diabetic retinopathy
by: Ning Han, et al.
Published: (2025-04-01)

Editorial: Exploring KLF4’s role in immune cell function and disease progression
by: H. Daniel Lacorazza, et al.
Published: (2025-08-01)

WCN24-2349 MUSCLE QUALITY IN CHRONIC KIDNEY DISEASE
by: F.E.R.N.A.N.D.O. MARGULIS, et al.
Published: (2024-04-01)

WCN24-964 PLASMAPHERESIS IN NEUROLOGICAL DISEASES PERFORMED BY NEPHROLOGISTS
by: Maria Emilia Guerrero, et al.
Published: (2024-04-01)

The impact of KLF2 modulation on the transcriptional program and function of CD8 T cells.
by: Gavin C Preston, et al.
Published: (2013-01-01)

WCN24-647 MONITORING DIABETIC KIDNEY DISEASE USING THE NORA MOBILE APP. PILOT STUDY RESULTS
by: Maria Jose Soler, et al.
Published: (2024-04-01)

WCN24-213 DIABETIC KIDNEY DISEASE AND NUMBER OF URINARY EXFOLIATED PROXIMAL TUBULE CELLS: IS THERE A LINK?
by: Henry HL. Wu, et al.
Published: (2024-04-01)

KLF9 in cancer: a potential prognostic marker and therapeutic target
by: Xiaoxiao Xiao, et al.
Published: (2025-08-01)

Insights into the Efficacy of GLP-1 Agonists and Dual Agonists: Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes
by: Laura Opalska, et al.
Published: (2024-12-01)

WCN24-786 PHASE I DOSE ESCALATION STUDY OF SHR6508, A CALCIUM-SENSING RECEPTOR AGONIST, IN HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM
by: Zhiming Ye, et al.
Published: (2024-04-01)

Transcription factor KLF2 is associated with the dysfunctional status of NK cells and the prognosis of pediatric B-ALL patients
by: Fang Wu, et al.
Published: (2025-01-01)

WCN24-2076 Proteonano™: a novel deep proteomics platform with 1000plex profiling capacity and picogram sensitivity and its application in diabetic kidney disease
by: ZHAO BAN, et al.
Published: (2024-04-01)

WCN24-2434 SIGNIFICANCE OF COEXISTENT NON-DIABETIC RENAL PATHOLOGY IN TYPE II DIABETIC KIDNEY DISEASE PATIENTS ON RENAL BIOPSY
by: Manoj Jain, et al.
Published: (2024-04-01)